Rigel Pharmaceuticals, Inc. (RIGL)

US — Healthcare Sector
Peers: CRIS  CRVS  IMMP  VSTM 

Automate Your Wheel Strategy on RIGL

With Tiblio's Option Bot, you can configure your own wheel strategy including RIGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RIGL
  • Rev/Share 14.9802
  • Book/Share 4.5812
  • PB 6.4394
  • Debt/Equity 0.745
  • CurrentRatio 2.0245
  • ROIC 0.7218

 

  • MktCap 529151530.0
  • FreeCF/Share 3.6986
  • PFCF 7.9993
  • PE 5.3936
  • Debt/Assets 0.2953
  • DivYield 0
  • ROE 4.3889

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 3
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
RIGL
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read More
image for news Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
RIGL
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.

Read More
image for news Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
RIGL
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.

Read More
image for news Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
RIGL
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.

Read More
image for news RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

About Rigel Pharmaceuticals, Inc. (RIGL)

  • IPO Date 2000-11-29
  • Website https://www.rigel.com
  • Industry Biotechnology
  • CEO Raul R. Rodriguez
  • Employees 162
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.